Minnesota Attorney General Keith Ellison is naming members of the family behind opioid manufacturer Purdue Pharma in the state's ongoing lawsuit over marketing tactics that have been linked to a wave of addictions and overdose deaths across the country.
The move, announced on Friday, follows lawsuits in other states against the Sackler family, whose members are known nationally for their philanthropic giving and as the makers of the widely prescribed medication OxyContin.
"Their misconduct led directly to damage and death in every community in Minnesota," Ellison said. "They knew what they were doing, and they did it anyway. Today, we're holding them personally accountable for the harm they and their greed have done to the people of our state."
In a statement Friday, the Sackler family described the lawsuit as "baseless" and a "misguided attempt to place blame where it does not belong for a complex public health crisis."
"We strongly deny these allegations, which are inconsistent with the factual record, and will vigorously defend against them," the family said. "Solving this crisis will require collaboration and focus on the real problems our nation needs to address. Government data makes clear that the opioid crisis is growing rapidly because of illicit fentanyl smuggled in from China and Mexico — and headline-seeking lawsuits like this only distract from the important task of identifying real solutions to that crisis."
Purdue Pharma notched a legal win this week when a North Dakota judge dismissed that state's claim that the company minimized risks and inflated the benefits of long-term use of its narcotic painkillers. The judge found "holding Purdue solely responsible for the entire opioid epidemic in North Dakota is difficult especially given Purdue's small share of the overall market for lawful opioids."
North Dakota Attorney General Wayne Stenehjem said Friday he will appeal the ruling.
Minnesota originally filed suit last year against Purdue Pharma, the Sackler-founded company in Connecticut that created OxyContin. The litigation was modeled after successful efforts to sue tobacco companies, with the aim of using a judgment to fund addiction treatment.